A Proactive Approach to Age-Related Macular Degeneration

The first commercial instrument avaliable that accurately measures macular protective pigment density (MPPD), in order to proactively treat one of the major risk factors for Age-related Macular Degeneration (AMD).

New technology, based on groundbreaking research, can predict the level of risk associated with developing AMD.

Macular degeneration is the leading cause of legal blindless in the world today. It currently affects over 30 million people worldwide. If this trend continues, the number will double in the next 20 to 30 years. Degeneration of the macula, the portion of the eye that is responsible for crisp straight ahead vision, i.e. reading and driving, is the primary cause of central vision loss. The disease is classfield in two overall categories, wet and dry.

Approximately 90% of all cases are dry, or age-related, while only 10 % are wet types. While macular degeneration affects approximately 27% of the worldwide population over the age of 55 years of age, physiologic changes can now be detected at a much earlier age. According to the National Eye Institute, "Macular degeneration will soon take on aspects of epidemic proportion." Early detection of AMD or, more importantly, early detection of one of its major risk factors, PRIOR TO SYMPTOMATOLOGY, and monitoring its status are critical to preserving vision. Up until now, this was not it is! With the use of our patented MacuScope™, protective pigment deficiencies in the macula, proven to be a major contributor to AMD, are now detectable and treatable.

As AMD reaches epidemic proportions, it is incumbent on all eye care professionals to offer this test to their appropriate patient population. Early detection of risk factors is essential to preserve long-term vision, considering that damage to the delicate macular tissue is cumulative and permanent.

The MacuScope™, after a painless, non-invasive, brief examination, is able to track protective pigment density changes in the macula. This places patients in one of two categories: high risk or low risk for the potential of developing AMD. A treatment program, using ocular supplements, could then be developed by the eye care professional to re-pigment the macula. The macular protective pigment is essential for absorbing damaging high-energy blue light, and has anti-oxidative properties, which eliminate harmful free radicals.

  • First commercially available instrument that accurately measures macular protective pigment density (MPPD)
  • Proven standard methodology for measuring MPPD
  • Validated by researchers worldwide
  • For use by all primary eye care professionals
  • Non-invasive, painless, safe and effective
  • Test takes approximately 2-3 minutes per patient
  • Cost Effective
  • Practice building, referral generating
  • FDA registered